Resource Summary Report

Generated by NIF on Aug 26, 2026

NOD-Prkdc^{em26Cd52}Il2rg/NjuCrl

RRID:IMSR_CRL:572
Type: Organism

Proper Citation

RRID:IMSR_CRL:572

Organism Information

URL: http://www.criver.com/products-services/basic-research/find-a-model/ncg-mouse

Proper Citation: RRID:IMSR_CRL:572

Description: Mus musculus with name NOD-Prkdc^{em26Cd52}Il2rg/NjuCrl from IMSR.

Species: Mus musculus

Synonyms: NOD-Prkdc Il2rg/NjuCrl. NOD-Prkdc Il2rg/NjuCrl. NCG mice. NOD/ShiLtJGpt-Prkdc Il2rg/GptCrl

Notes: gene symbol note: interleukin 2 receptor; gamma chain|protein kinase; DNA activated; catalytic polypeptide; coisogenic strain: Il2rg|Prkdc

Affected Gene: interleukin 2 receptor; gamma chain|protein kinase; DNA activated; catalytic polypeptide

Catalog Number: CRL:572

Database: Charles River Laboratories

Database Abbreviation: CRL

Availability: live

Organism Name: NOD-Prkdc^{em26Cd52}Il2rg/NjuCrl

Record Creation Time: 20250513T062410+0000

Record Last Update: 20260815T055928+0000

Ratings and Alerts

No rating or validation information has been found for NOD-Prkdc^{em26Cd52}Il2rg/NjuCrl.

No alerts have been found for NOD-Prkdc^{em26Cd52}Il2rg/NjuCrl.

Data and Source Information

Source: Integrated Animals

Source Database: Charles River Laboratories

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Qin M, et al. (2026) SLC13A2-transported citrate remodels transcriptional regulation through protein acetylation to suppress tumor growth. Science advances, 12(15), eaec4368.

Pastrana CC, et al. (2026) Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage. Cancer research, 86(14), 3537.

Fenoglio S, et al. (2026) Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens. Cell reports methods, 6(7), 101470.

Cheng J, et al. (2025) Targeting intracellular LMP2 with costimulatory signal-armed antibody-like TCR T cells. JCI insight, 10(10).

Zhong M, et al. (2025) Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma. Clinical epigenetics, 17(1), 74.

Cheng Y, et al. (2025) Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Molecular therapy : the journal of the American Society of Gene Therapy, 33(4), 1535.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine, 6(11), 102446.

Chatterjee D, et al. (2025) KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance. Molecular cancer research : MCR, 23(6), 553.

Conn BP, et al. (2025) Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell reports methods, 5(5), 101049.

Gaspar M, et al. (2025) An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. Journal for immunotherapy of cancer, 13(8).

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

Duan H, et al. (2024) Chiglitazar diminishes the warburg effect through PPAR? /mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia. Experimental hematology & oncology, 13(1), 121.

Skidmore LK, et al. (2024) Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Molecular cancer therapeutics, 23(12), 1842.

Baldwin JG, et al. (2024) Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy. Cell.

Lazure F, et al. (2023) Transcriptional reprogramming of skeletal muscle stem cells by the niche environment. Nature communications, 14(1), 535.

Deng M, et al. (2023) The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. Scientific reports, 13(1), 18554.

Gutierrez-Barbosa H, et al. (2023) A Comparison of Lymphoid and Myeloid Cells Derived from Human Hematopoietic Stem Cells Xenografted into NOD-Derived Mouse Strains. Microorganisms, 11(6).

Antal CE, et al. (2023) A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Nature communications, 14(1), 5195.

Kemper K, et al. (2022) Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. Life science alliance, 5(11).

Demeule M, et al. (2022) The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells. Pharmaceutics, 14(9).